[HTML][HTML] Tiotropium/olodaterol: a review in COPD
HA Blair - Drugs, 2019 - Springer
Abstract Tiotropium/olodaterol (Stiolto® Respimat®; Spiolto® Respimat®) is an inhaled fixed-
dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter …
dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter …
Recommendations for COPD management in Central and Eastern Europe
A Valipour, Z Aisanov, S Avdeev… - Expert Review of …, 2022 - Taylor & Francis
ABSTRACT Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
strategy report provides guidance on effective management of chronic obstructive …
strategy report provides guidance on effective management of chronic obstructive …
[HTML][HTML] Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis
M Miravitlles, JL García-Rivero, X Ribera, J Galera… - Respiratory …, 2022 - Springer
Background Persistent airflow limitation and dyspnoea may reduce chronic obstructive
pulmonary disease (COPD) patients exercise capacity and physical activity, undermining …
pulmonary disease (COPD) patients exercise capacity and physical activity, undermining …
[HTML][HTML] COPD in firefighters: a specific event-related condition rather than a common occupational respiratory disorder
AG Rajnoveanu, RM Rajnoveanu, NS Motoc… - Medicina, 2022 - mdpi.com
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality
worldwide. Smoking remains the most important risk factor, but occupational exposures may …
worldwide. Smoking remains the most important risk factor, but occupational exposures may …
Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
R Dhand, J Eicher, M Hänsel, I Jost… - … Journal of Chronic …, 2019 - Taylor & Francis
Purpose The Respimat is a handheld, propellant-free, soft-mist inhaler. Observations by
patients and physicians prompted development of an improved second-generation …
patients and physicians prompted development of an improved second-generation …
[HTML][HTML] Effects of tiotropium/olodaterol on activity-related breathlessness, exercise endurance and physical activity in patients with COPD: narrative review with meta …
F Maltais, A de la Hoz, R Casaburi, D O'Donnell - Advances in therapy, 2021 - Springer
One of the most debilitating symptoms of chronic obstructive pulmonary disease (COPD) is
breathlessness, which leads to avoidance of physical activities in daily living and hastens …
breathlessness, which leads to avoidance of physical activities in daily living and hastens …
Therapeutic success of tiotropium/olodaterol, measured using the clinical COPD questionnaire (CCQ), in routine clinical practice: a multinational non-interventional …
A Valipour, S Avdeev, A Barczyk, V Bayer… - … journal of chronic …, 2021 - Taylor & Francis
Background The Clinical COPD Questionnaire (CCQ) is a simple patient-reported tool to
measure clinical control of chronic obstructive pulmonary disease (COPD). Objective This …
measure clinical control of chronic obstructive pulmonary disease (COPD). Objective This …
[HTML][HTML] Targeting exertional breathlessness to improve physical activity: the role of primary care
M Román-Rodríguez, JWH Kocks - NPJ Primary Care Respiratory …, 2021 - nature.com
Primary care physicians (PCPs) play a crucial role in the diagnosis and management of
chronic obstructive pulmonary disease (COPD). By working together with patients to target …
chronic obstructive pulmonary disease (COPD). By working together with patients to target …
[HTML][HTML] Assessment of Patient Experiences with Respimat® in Everyday Clinical Practice
C Taube, V Bayer, CM Zehendner, A Valipour - Pulmonary Therapy, 2020 - Springer
Introduction Chronic obstructive pulmonary disease (COPD) is a progressive disease
requiring maintenance therapy. According to the Global Initiative for Chronic Obstructive …
requiring maintenance therapy. According to the Global Initiative for Chronic Obstructive …
[HTML][HTML] EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or …
R Buhl, M Dreher, M Mattiucci-Guehlke… - Advances in …, 2023 - Springer
Abstract Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD
2023) no longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid …
2023) no longer recommends a long-acting β2-agonist (LABA) plus inhaled corticosteroid …